During the past decade, ASST PAPA GIOVANNI XXIII; Ematologia conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 6 clinical trials were completed, i.e. on average, 26.1% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 3 clinical trials were completed. i.e. 23.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ASST PAPA GIOVANNI XXIII; Ematologia" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 11 trials, followed by "Hoffmann-La Roche" with 10 trials sponsored, "Gruppo Italiano Trapianto di Midollo Osseo" with 8 trials sponsored, "Northern Italy Leukemia Group" with 4 trials sponsored and "Celgene" with 4 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ASST PAPA GIOVANNI XXIII; Ematologia" #1 collaborator was "Azienda Policlinico Umberto I" with 2 trials as a collaborator, "AOP Orphan Pharmaceuticals AG" with 1 trials as a collaborator, "Associazione Italiana di Immunogenetica e Biologia dei Trapianti (AIBT)" with 1 trials as a collaborator, "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator and "Institute of Cancer Research, United Kingdom" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "ASST PAPA GIOVANNI XXIII; Ematologia" are "Acute Myeloid Leukemia" (3 trials), "Hematologic Diseases" (3 trials), "Lymphoma, Non-Hodgkin" (3 trials), "Acute Lymphoblastic Leukemia" (2 trials) and "Multiple Myeloma" (2 trials). Many other conditions were trialed in "ASST PAPA GIOVANNI XXIII; Ematologia" in a lesser frequency.

Most popular intervention types in "ASST PAPA GIOVANNI XXIII; Ematologia" are "Drug" (29 trials), "Other" (4 trials), "Procedure" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Tocilizumab" (5 trials), "Glofitamab" (4 trials), "Obinutuzumab" (4 trials), "Cyclophosphamide" (2 trials) and "Dexamethasone" (2 trials). Other intervention names were less common.

The vast majority of trials in "ASST PAPA GIOVANNI XXIII; Ematologia" are 40 trials for "All" genders.

Currently, there are NaN active trials in "ASST PAPA GIOVANNI XXIII; Ematologia". undefined are not yet recruiting, 10 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in ASST PAPA GIOVANNI XXIII; Ematologia, 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in ASST PAPA GIOVANNI XXIII; Ematologia, 7 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".